Lantian Lu graduated with a B.Eng in pharmaceutical sciences (biopharmaceutical concentration) from Zhejiang University of Technology in 2018. He studied medicinal chemistry and biochemical engineering at UCSD and UW-Madison in 2016 and 2017, respectively. He received his Master's degree in biotechnology at the University of Queensland (Australia) in 2020. Then, he started his Ph.D. in vaccine development in the group of Professor Istvan Toth in January 2021, working on novel vaccine delivery system designs for infectious diseases. He is also affiliated with Hangzhou Neoantigen Therapeutics Co. Ltd, working on the development of neoantigen-based cancer immunotherapies.
Lantian Lu graduated with a B.Eng in pharmaceutical sciences (biopharmaceutical concentration) from Zhejiang University of Technology in 2018. He studied medicinal chemistry and biochemical engineering at UCSD and UW-Madison in 2016 and 2017, respectively. He received his Master's degree in biotechnology at the University of Queensland (Australia) in 2020. Then, he started his Ph.D. in vaccine development in the group of Professor Istvan Toth in January 2021, working on novel vaccine delivery system designs for infectious diseases. He is also affiliated with Hangzhou Neoantigen Therapeutics Co. Ltd, working on the development of neoantigen-based cancer immunotherapies.